Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium

Asparaginase (ASNase) is an important anti-leukaemic drug in the treatment of childhood acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL). A substantial proportion of patients develop hypersensitivity reactions with anti-ASNase neutralising antibodies, resulting in allergic reactions or silent inactivation (SI), and characterised by inactivation and rapid clearance of ASNase. We report results of a prospective, real-time therapeutic drug monitoring of pegylated Escherichia coli (PEG-)ASNase and Erwinia ASNase in children treated for ALL and NHL in Belgium. Erwinia ASNase was g... Mehr ...

Verfasser: Mondelaers, Veerle
Ferster, Alina
Uyttebroeck, Anne
Brichard, Bénédicte
van der Werff Ten Bosch, Jutte
Norga, Koenraad
Francotte, Nadine
Piette, Caroline
Vandemeulebroecke, Katrien
Verbeke, Charlotte
Schmidt, Susanne
Benoît, Yves
Lammens, Tim
De Moerloose, Barbara M J B.
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Schlagwörter: Hématologie / acute lymphoblastic leukaemia / allergy / asparaginase / childhood / silent inactivation / therapeutic drug monitoring
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28957477
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/303265